OTIC - オトノミ― (Otonomy Inc.) オトノミ―

 OTICのチャート


 OTICの企業情報

symbol OTIC
会社名 Otonomy Inc (オトノミ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オトノミ(Otonomy Inc.)はバイオ医薬品会社である。同社は耳疾患・障害の治療薬の開発・製品化に従事する。同社の製品候補には、OTIPRIO、OTO-104、OTO-311がある。 OTIPRIOは、医師が投与する単回用量の抗菌剤であり、鼓膜瘻造設術(TTP)手術を受けた輸液による両側性中耳炎の小児患者の治療に使用され、商業的に購入することができる。OTO-104は、メニエール病および他の内耳状態の治療用の開発中のステロイドデキサメタゾンの持続曝露製剤である。OTO-311は、耳鳴りの治療用の開発中のN-メチル-D-アスパラギン酸(NMDA)受容体拮抗薬ガシクリジンの持続曝露製剤である。また、年齢関連の難聴(老人性難聴)などの感音難聴を対象とした他の多様な製品候補を有する。   オトノミ―は、米国の臨床段階のバイオ医薬品企業。耳の疾患および障害のための治療薬の開発と商業化に焦点を当てる。「AurionPro」は、鼓膜切開チュ―ブの配置手術時に中耳滲出の小児患者のための抗生物質シプロフロキサシン製剤、「OTO-104」は、メニエ―ル病患者の治療のためにステロイド・デキサメタゾンの製剤などを提供する。   Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
本社所在地 4796 Executive Drive San Diego CA 92121 USA
代表者氏名 Jay Lichter ジェイ・ライヒター
代表者役職名 Independent Chairman of the Board
電話番号 +1 619-323-2200
設立年月日 39569
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.otonomy.com
nasdaq_url https://www.nasdaq.com/symbol/otic
adr_tso
EBITDA EBITDA(百万ドル) -64.93600
終値(lastsale) 2.75
時価総額(marketcap) 84232843.75
時価総額 時価総額(百万ドル) 79.63832
売上高 売上高(百万ドル) 0.97600
企業価値(EV) 企業価値(EV)(百万ドル) -20.36968
当期純利益 当期純利益(百万ドル) -64.80800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Otonomy Inc revenues decreased 38% to $424K. Net loss decreased 50% to $25M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative - other decrease of 65% to $7M (expense) Research and developme decrease of 51% to $11.5M (expense) Interest income increase of 24% to $763K (income).

 OTICのテクニカル分析


 OTICのニュース

   Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting  2021/09/27 11:30:00 Intrado Digital Media
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-413 Phase 1/2 trial at the upcoming American Academy of Otolaryngology Head and Neck Surgery (AAO-HNS) Annual Meeting to be held in Los Angeles October 3-6, 2021. The oral presentation will be delivered on October 3, 2021 at 3:15 p.m. PT by Peter G. Volsky, M.D., Assistant Professor of Otology and Neurotology at Eastern Virginia Medical School. Dr. Volsky was an investigator in the trial during his prior clinical service with South Florida ENT Associates.
   Otonomy to Participate in Two Upcoming Investor Conferences  2021/09/02 11:30:00 Intrado Digital Media
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming virtual conferences:
   Otonomy Appoints Jill Broadfoot to Board of Directors  2021/08/19 11:30:00 Intrado Digital Media
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors.
   The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma  2021/08/12 12:09:26 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI ) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) Aptose Biosciences Inc.
   Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update  2021/08/04 20:16:00 Intrado Digital Media
Conference call and webcast today at 4:30 p.m. ET
   Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows  2021/05/14 18:59:13 Benzinga
Otonomy Inc (NASDAQ: OTIC ) may have hit a snag with the development of its lead ear disorder candidate Otividex . Still, the company is trumpeting an early win for a gene therapy designed to treat congenital hearing loss. The drug candidate, dubbed OTO-825, reduced hearing loss and repaired structural damage in the inner ear in two mouse models of genetically driven hearing deficiency. Otonomy and its partner Applied Genetic … Full story available on Benzinga.com
   The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron  2021/05/12 12:57:17 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aptinyx Inc. (NASDAQ: APTX ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) (reacted to its first-quarter results) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings  2021/05/11 11:54:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Athersys, Inc. (NASDAQ: ATHX ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) (reacted to publication of positive results for a late-stage asset in lupus nephritis) Autolus Therapeutics plc (NASDAQ: AUTL ) AVROBIO, Inc.
   Otonomy stock loses half its value after disappointing trial results of vertigo treatment  2021/02/22 13:37:26 MarketWatch
Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's…
   Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd  2020/11/11 18:29:20 OpenPR
Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,
   Otonomy stock loses half its value after disappointing trial results of vertigo treatment  2021/02/22 13:37:26 MarketWatch
Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's…
   Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd  2020/11/11 18:29:20 OpenPR
Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,
   Global Meniere's Disease Drug Market to Register Substantial Global Expansion by 2027, Get Understanding of COVID 19 effect on Industry: Abbott, Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical  2020/11/06 15:05:35 OpenPR
Global Meniere's Disease Drug Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the
   Otonomy, Inc. (NASDAQ:OTIC) Given Consensus Recommendation of “Buy” by Brokerages  2020/10/24 14:07:00 The Olympia Report
Otonomy, Inc. (NASDAQ:OTIC) has earned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on […]
   Booming Growth of Vertigo Drugs Market to Witness a Pronounce Growth at CAGR during 2020-2027| Auris Medical , Otonomy , Sensorion , Sound Pharmaceuticals  2020/10/15 10:18:37 OpenPR
The global analysis of Vertigo Drugs Market and its upcoming prospects have recently added by HealthCare Intelligence Markets to its extensive repository. It has been employed through the primary and secondary research methodologies. This market is expected to become competitive

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オトノミ― OTIC Otonomy Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)